Renovaro Biosciences Appoints Two Finance Industry Experts to Board of Directors

Renovaro Biosciences Inc., a leading biotechnology firm specializing in cell, gene, and immunotherapy for solid tumors with short life expectancy, has made two significant appointments to its Board of Directors. Leni Boeren and Ruud Hendriks, both highly experienced professionals in finance and business, have joined Renovaro as Independent Directors.

Leni Boeren brings an impressive 40-year career in the financial sector, with notable roles at Paribas, Rabobank, Amsterdam Exchanges, and Euronext. She has also held executive positions at international asset management firms, including Robeco Groep N.V. Leni currently holds non-executive positions with NIBC Bank, Air France-KLM, Ohpen, and Mollie, and serves on the Capital Market Committee of the Dutch regulator.

Ruud Hendriks boasts over 35 years of experience in the asset management industry. He held senior roles at renowned financial institutions such as Goldman Sachs Asset Management and Robeco Group. Ruud is currently a senior advisor to Pictet Group and Van Lanschot Kempen N.V., and he also advises wealthy individuals. Additionally, he serves as an Ambassador to Add Value Fund Management B.V.

Rene Sindlev, Chairman of Renovaro, expressed his delight in welcoming Leni and Ruud to the Board, emphasizing their extensive experience in capital markets and asset management. He believes their financial and business expertise will be invaluable as Renovaro progresses towards commercialization.

Leni Boeren expressed her excitement about joining Renovaro’s Board during this crucial phase of the company’s journey. She looks forward to supporting the company in unlocking the vast potential of the planned combination with GEDiCube, which will leverage cutting-edge AI technology and pioneering biotherapeutics to advance the battle against cancer and other diseases.

Ruud Hendriks also expressed his honor in being part of the journey towards combining Renovaro and GEDiCube. He believes that the integration of these innovative platforms in AI and biotherapeutics will provide comprehensive solutions to transform patient care worldwide.

Renovaro Biosciences Inc. has developed advanced cell, gene, and immunotherapy platforms aimed at enhancing the body’s natural ability to fight tumors and infectious diseases. The company is committed to spearheading advancements in the field, leveraging state-of-the-art AI technology and groundbreaking biotherapeutics.

With the addition of Leni Boeren and Ruud Hendriks to its Board of Directors, Renovaro is well-positioned to capitalize on their expertise and drive forward its mission to revolutionize patient care. The company’s planned combination with GEDiCube is set to create a powerful force in the biotechnology industry, offering innovative solutions for the benefit of patients and their families worldwide.

For more information about Renovaro Biosciences Inc., please visit their website at www.renovarobio.com.